DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
AT7519 is an investigational drug.
There have been 5 clinical trials for AT7519. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Lymphoma, Mantle-Cell. The leading clinical trial sponsors are NCIC Clinical Trials Group, Astex Pharmaceuticals, and National Cancer Institute (NCI).
There are twenty-two US patents protecting this investigational drug and two hundred and thirty-one international patents.
Recent Clinical Trials for AT7519
|Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery||National Cancer Institute (NCI)||Phase 1|
|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia||Astex Pharmaceuticals||Phase 2|
|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia||NCIC Clinical Trials Group||Phase 2|
Top disease conditions for AT7519
Top clinical trial sponsors for AT7519
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AT7519||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|AT7519||Start Trial||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|AT7519||Start Trial||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|